Literature DB >> 3525614

Stable isotopes in pharmacology studies: present and future.

T R Browne.   

Abstract

Stable-isotope techniques offer advantages over older methods in safety, sensitivity, specificity, and reduction in numbers of subjects required and analytic determinations for some types of pharmacology studies. In addition to their use as internal standards in gas chromatography-mass spectrometry analytic methods, stable isotopes have been successfully employed in studies of absorption, bioavailability, distribution, biotransformation, excretion, metabolite identification, time-dependent and dose-dependent pharmacokinetic changes, drug interactions, pharmacologic changes during pregnancy, mutagenicity, and teratogenicity.

Mesh:

Substances:

Year:  1986        PMID: 3525614     DOI: 10.1002/j.1552-4604.1986.tb03563.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  4 in total

1.  Automated detection of inaccurate and imprecise transitions in peptide quantification by multiple reaction monitoring mass spectrometry.

Authors:  Susan E Abbatiello; D R Mani; Hasmik Keshishian; Steven A Carr
Journal:  Clin Chem       Date:  2009-12-18       Impact factor: 8.327

Review 2.  Applications of stable isotopes in clinical pharmacology.

Authors:  Reinout C A Schellekens; Frans Stellaard; Herman J Woerdenbag; Henderik W Frijlink; Jos G W Kosterink
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

3.  Steady-state carbamazepine pharmacokinetics following oral and stable-labeled intravenous administration in epilepsy patients: effects of race and sex.

Authors:  S E Marino; A K Birnbaum; I E Leppik; J M Conway; L C Musib; R C Brundage; R E Ramsay; P B Pennell; J R White; C R Gross; J O Rarick; U Mishra; J C Cloyd
Journal:  Clin Pharmacol Ther       Date:  2012-01-25       Impact factor: 6.875

Review 4.  Stable Isotopically Labeled Intravenous Microdose Pharmacokinetic Trials as a Tool to Assess Absolute Bioavailability: Feasibility and Paradigm to Apply for Protein Kinase Inhibitors in Oncology.

Authors:  Jeroen Roosendaal; Hilde Rosing; Jos H Beijnen
Journal:  Clin Pharmacol Drug Dev       Date:  2020-06-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.